Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures

被引：48

作者：

Carnio, Simona ^{[1
]}

Novello, Silvia ^{[1
]}

Papotti, Mauro ^{[1
]}

Loiacono, Marco ^{[1
]}

Scagliotti, Giorgio Vittorio ^{[1
]}

机构：

[1] Univ Torino, Dept Oncol, Turin, Italy

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2013年 / 2卷 / 05期

关键词：

Prognostic and predictive biomarkers; early stages; non-small cell lung cancer (NSCLC); gene signatures;

D O I：

10.3978/j.issn.2218-6751.2013.10.05

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In early stage non-small cell lung cancer (NSCLC) large randomized trials have demonstrated that in patients with radically resected disease adjuvant chemotherapy improves 5-year survival rates. However, a customization of systemic treatment is needed to avoid treatments in patients cured by surgery alone or to justify the use of adjuvant chemotherapy in high risk patients, including those in stage IA. Recently, the possibility of identifying prognostic and predictive factors related to the genetic signatures of the tumor that could affect adjuvant and neo-adjuvant treatment choices for resectable non-small cell lung cancer (NSCLC) has been of interest. This review summarizes the current status and future opportunities for clinical application of genotyping and genomic tests in early NSCLC.

引用

页码：372 / 381

页数：10

共 88 条

[1]

Altaha R, 2004, INT J MOL MED, V14, P959

[2] Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer [J].

Arriagada, Rodrigo ;

Dunant, Ariane ;

Pignon, Jean-Pierre ;

Bergman, Bengt ;

Chabowski, Mariusz ;

Grunenwald, Dominique ;

Kozlowski, Miroslaw ;

Le Pechoux, Cecile ;

Pirker, Robert ;

Pinel, Maria-Izabel Sathler ;

Tarayre, Michele ;

Le Chevalier, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :35-42

[3] Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data [J].

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Tribodet, H. ;

Burdett, S. ;

Stewart, L. A. ;

Tierney, J. F. ;

Stephens, R. J. ;

Arriagada, R. ;

Higgins, J. P. ;

Johnson, D. H. ;

van Meerbeeck, J. ;

Parmar, M. K. B. ;

Souhami, R. L. ;

Bergman, B. ;

Dautzenberg, B. ;

Douillard, J. Y. ;

Dunant, A. ;

Endo, C. ;

Girling, D. J. ;

Imaizumi, M. ;

Kato, H. ;

Keller, S. M. ;

Kimura, H. ;

Knuuttila, A. ;

Kodama, K. ;

Komaki, R. ;

Kris, M. G. ;

Lad, T. ;

Mineo, T. ;

Park, J. H. ;

Piantadosi, S. ;

Pyrhonen, S. ;

Rosell, R. ;

Scagliotti, G. V. ;

Seymour, L. W. ;

Shepherd, F. A. ;

Spiro, S. G. ;

Strauss, G. M. ;

Sylvester, R. ;

Tada, H. ;

Tanaka, F. ;

Torri, V. ;

Wada, H. ;

Waller, D. ;

Xu, G. C. .

LANCET, 2010, 375 (9722) :1267-1277

[4] Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer [J].

Baillie, R ;

Carlile, J ;

Pendleton, N ;

Schor, AM .

JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (02) :116-120

[5] RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer [J].

Bepler, G ;

Sharma, S ;

Cantor, A ;

Gautam, A ;

Haura, E ;

Simon, G ;

Sharma, A ;

Sommers, E ;

Robinson, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1878-1885

[6] Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer [J].

Bepler, Gerold ;

Sommers, K. Eric ;

Cantor, Alan ;

Li, Xueli ;

Sharma, Anupama ;

Williams, Charles ;

Chiappori, Alberto ;

Haura, Eric ;

Antonia, Scott ;

Tanvetyanon, Tawee ;

Simon, George ;

Obasaju, Coleman ;

Robinson, Lary A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) :1112-1118

[7] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].

Bepler, Gerold ;

Kusmartseva, Irina ;

Sharma, Swati ;

Gautam, Ashish ;

Cantor, Alan ;

Sharma, Anupama ;

Simon, George .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737

[8] ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis [J].

Bepler, Gerold ;

Olaussen, Ken Andre ;

Vataire, Anne-Lise ;

Soria, Jean-Charles ;

Zheng, Zhong ;

Dunant, Ariane ;

Pignon, Jean-Pierre ;

Schell, Michael J. ;

Fouret, Pierre ;

Pirke, Robert ;

Filipits, Martin ;

Brambilla, Elisabeth .

AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (01) :69-78

[9] Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. [J].

Capelletti, M. ;

Wang, X. F. ;

Gu, L. ;

Graziano, S. L. ;

Kratzke, R. A. ;

Strauss, G. M. ;

Maddaus, M. ;

Green, M. R. ;

Vokes, E. E. ;

Janne, P. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[10] ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine [J].

Ceppi, P. ;

Volante, M. ;

Novello, S. ;

Rapa, I. ;

Danenberg, K. D. ;

Danenberg, P. V. ;

Cambieri, A. ;

Selvaggi, G. ;

Saviozzi, S. ;

Calogero, R. ;

Papotti, M. ;

Scagliotti, G. V. .

ANNALS OF ONCOLOGY, 2006, 17 (12) :1818-1825

← 1 2 3 4 5 6 7 8 9 →